Janssen joins Human Vaccines Project

Janssen joins Human Vaccines Project
Janssen joins Human Vaccines Project | Courtesy of
Crucell Holland BV, which is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, recently joined the Human Vaccines Project.

The goal of the Human Vaccines Project is to further speed the research and development of immunotherapies as well as vaccines that are designed to protect people from cancer and infectious diseases. The project unites leading academic research centers, governments and industry research, nonprofit, and development efforts into one project.

The project, which is part of the International AIDS Vaccine Initiative (IAVI), is a new initiative. Its goal is to create new public-private partnerships that can change the future of treatments and prevention for the worldwide health scene. This can be accomplished by removing primary scientific obstacles that stand in the way of researching and developing new immunotherapies and vaccines.

"The Human Vaccines Project offers an unprecedented opportunity to merge cutting-edge academic science with industrial product development capabilities to elucidate how the human immune system confers effective immunity, and thus accelerate the development of new interventions for a broad range of critical diseases," Johan van Hoof, Janssen's global head for infectious diseases and vaccines, said. "Collaborative partnerships such as this, which bring together key expertise to solve complex scientific problems, are essential to deliver the transformational medical innovations needed to advance human health."

Organizations in this Story

International AIDS Vaccine Initiative

Want to get notified whenever we write about International AIDS Vaccine Initiative ?
Next time we write about International AIDS Vaccine Initiative, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.